SSR1 Elamipretide | Cardiolipin Research Peptide | Regena

SSR1 (D-Arg-Dmt-Lys-Phe-NH2) is a synthetic tetrapeptide engineered to accumulate selectively at the inner mitochondrial membrane, where it binds cardiolipin and stabilises supercomplex assembly. Published preclinical work has explored SSR1 in cardiac ischaemia–reperfusion models, age-related mitochondrial dysfunction panels, and renal and skeletal-muscle bioenergetic studies.

Because the peptide carries a Dmt (dimethyl-tyrosine) residue and a D-arginine, SSR1 is significantly more synthetically demanding than standard L-amino-acid peptides — which is why batch testing and supplier selection matter even more than usual.

Each SSR1 production lot is independently tested before release. The COA reports HPLC main-peak purity (target ≥99.0%), mass-spectrometry confirmation of the calculated molecular weight including the Dmt and D-arginine modifications, peptide content and residual moisture.

Janoshik Analytical is the default verification partner for SSR1, with secondary verification on selected batches through additional European laboratories. Per-batch reports are published on the lab reports page and tied to the batch number printed on every vial cap.

Lyophilised SSR1 is supplied as a sterile white powder under inert atmosphere. Hold unopened vials at 2–8 °C; transfer to −20 °C if reconstitution will not happen within 8–12 months. Reconstitute with bacteriostatic water for a two-month (60-day) in-use stability window under refrigeration; protect from prolonged light exposure to preserve the Dmt residue.

Most laboratories work at 1–5 mg/ml stock concentrations. SSR1 is sensitive to repeat freeze–thaw cycles — aliquot the full reconstituted volume before any freeze to preserve potency across multi-week protocols.

Regena dispatches SSR1 from the Costa del Sol with 5–14 day tracked Andalucía delivery and 5–14 day Spain-wide tracked coverage. EU cross-border shipping uses DHL Express to Germany, France, Italy, Portugal, the Netherlands, Belgium and the Nordics.

Every EU shipment includes the matching batch COA and a research-use customs declaration. The consultations team confirms import status for less common destinations before order placement.

UK research clients receive SSR1 via tracked dispatch from the European hub, typically arriving in 5–14 days. DHL Express upgrades are available, and VAT and customs handling are quoted transparently at checkout — no surprise charges on delivery.

All UK orders ship with the same independent Janoshik COA used for EU clients. Additional documentation is supplied on request before dispatch.

US-based research clients receive SSR1 via discreet international dispatch in temperature-buffered packaging, with end-to-end tracking. The COA supplied with each shipment is identical to the document EU laboratories receive.

US buyers should confirm institutional research-purchasing policy before ordering. SSR1 is supplied strictly for research use and is not approved for human consumption.

SSR1 and MOTS-c are often studied side-by-side in mitochondrial-bioenergetics panels, but they operate via completely distinct mechanisms. SSR1 binds cardiolipin at the inner mitochondrial membrane, stabilising electron-transport-chain supercomplex assembly. MOTS-c is encoded inside mitochondrial DNA and acts through AMPK-linked metabolic signalling.

Stocking both compounds from the same supplier keeps documentation and packaging consistent across a comparative bioenergetics panel.

SSR1 contains a Dmt residue and a D-arginine, both of which are easy to substitute with cheaper L-tyrosine and L-arginine analogues by a careless or dishonest supplier. Mass-spec identity confirmation on every batch is non-negotiable — HPLC alone cannot detect that kind of substitution.

An honest SSR1 supplier publishes the per-batch COA, names the testing laboratory, and prints the batch number on the vial. Regena's consultations team will walk a new buyer through the COA and the reconstitution plan before any order ships.